Drugs Stocks On The Rise With Help From 3 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 61 points (0.3%) at 18,072 as of Monday, June 1, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,805 issues advancing vs. 1,201 declining with 153 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Bristol-Myers Squibb Company ( BMY), up 3.3%, Alexion Pharmaceuticals ( ALXN), up 1.1%, Actavis ( ACT), up 0.8%, Amgen ( AMGN), up 0.7% and Abbott Laboratories ( ABT), up 0.9%. On the negative front, top decliners within the industry include Shire ( SHPG), down 1.3%, and GlaxoSmithKline ( GSK), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Perrigo ( PRGO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Perrigo is up $3.70 (1.9%) to $194.00 on light volume. Thus far, 449,577 shares of Perrigo exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $191.51-$194.22 after having opened the day at $191.70 as compared to the previous trading day's close of $190.30.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Perrigo has a market cap of $28.4 billion and is part of the health care sector. Shares are up 13.8% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate Perrigo a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Perrigo as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Perrigo Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, AbbVie ( ABBV) is up $0.36 (0.5%) to $66.95 on average volume. Thus far, 5.9 million shares of AbbVie exchanged hands as compared to its average daily volume of 12.3 million shares. The stock has ranged in price between $66.26-$67.26 after having opened the day at $66.80 as compared to the previous trading day's close of $66.59.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $107.5 billion and is part of the health care sector. Shares are up 1.8% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full AbbVie Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Gilead ( GILD) is up $1.95 (1.7%) to $114.22 on average volume. Thus far, 5.8 million shares of Gilead exchanged hands as compared to its average daily volume of 11.1 million shares. The stock has ranged in price between $112.65-$114.37 after having opened the day at $113.17 as compared to the previous trading day's close of $112.27.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $165.8 billion and is part of the health care sector. Shares are up 19.1% year-to-date as of the close of trading on Friday. Currently there are 13 analysts who rate Gilead a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%